Rapport Therapeutics Inc.

This study is testing whether an investigational drug called RAP-219 can safely and effectively treat acute manic episodes in people with bipolar I disorder. 224 adult participants experiencing a manic episode will receive either RAP-219 or a placebo during a 3-week inpatient sta…

This study is testing the long-term safety and effectiveness of an investigational drug called RAP-219 for adults with focal epilepsy that doesn't respond well to current medications. It follows 30 participants who have already completed a related short-term study to see how well…